Home
HALO
HALO News

Latest Halozyme Therapeutics Inc. (HALO) News on November 24, 2024

MT Newswires

a day ago

Sector Update: Health Care Stocks Rise Friday Afternoon

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Benzinga

a day ago

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why

Zacks

a day ago

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Zacks

a day ago

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Investing.com

2 days ago

Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

MT Newswires

2 days ago

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires

2 days ago

Update: Halozyme Therapeutics Withdraws Proposal to Acquire Evotec

MT Newswires

2 days ago

Sector Update: Health Care

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

2 days ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Zacks

4 days ago

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Zacks

4 days ago

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?

Zacks

4 days ago

Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Zacks

4 days ago

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

PR Newswire

6 days ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

Bloomberg

6 days ago

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Benzinga

8 days ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Zacks

8 days ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

MT Newswires

9 days ago

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Investing.com

9 days ago

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid

Halozyme bids for Evotec; BeiGene gets a new name

BioPharma Dive

9 days ago

Halozyme bids for Evotec; BeiGene gets a new name

Germany’s Evotec Gets Takeover Interest From Halozyme

Bloomberg

9 days ago

Germany’s Evotec Gets Takeover Interest From Halozyme

MT Newswires

9 days ago

Halozyme Proposes to Acquire Evotec for 11 Euros per Share

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

PR Newswire

9 days ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Argus Research

11 days ago

HALO: Rating decreased to a HOLD

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Zacks

16 days ago

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Argus Research

18 days ago

HALO: What does Argus have to say about HALO?

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

18 days ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

19 days ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St.

21 days ago

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Top High Growth Tech Stocks To Watch In November 2024

Simply Wall St.

22 days ago

Top High Growth Tech Stocks To Watch In November 2024

Halozyme Announces Record Earnings, Guidance

FX Empire

22 days ago

Halozyme Announces Record Earnings, Guidance

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Zacks

23 days ago

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

23 days ago

Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

23 days ago

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Zacks

23 days ago

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

MT Newswires

23 days ago

Halozyme Therapeutics Q3 Non-GAAP EPS, Revenue Increase

Associated Press Finance

23 days ago

Halozyme Therapeutics: Q3 Earnings Snapshot

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire

23 days ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

MT Newswires

a month ago

Halozyme Therapeutics Says European Patent Office Revoked DARZALEX Patent

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

PR Newswire

a month ago

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Halozyme to Report Third Quarter 2024 Financial and Operating Results

PR Newswire

a month ago

Halozyme to Report Third Quarter 2024 Financial and Operating Results

State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc

GuruFocus.com

a month ago

State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Zacks

a month ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

MT Newswires

a month ago

Halozyme Therapeutics Insider Sold Shares Worth $1,070,059, According to a Recent SEC Filing

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Zacks

a month ago

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Argus Research

2 months ago

HALO: Lowering target price to $68.00

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

2 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again

Zacks

2 months ago

Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again

MT Newswires

2 months ago

Wells Fargo Downgrades Halozyme Therapeutics to Equal Weight From Overweight, $62 Price Target

MT Newswires

2 months ago

Halozyme Therapeutics Expands Licensing Agreement With Argenx

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

PR Newswire

2 months ago

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

2 months ago

High Growth Tech Stocks In The United States To Watch

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

MT Newswires

2 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,706,440, According to a Recent SEC Filing

MT Newswires

2 months ago

JPMorgan Downgrades Halozyme Therapeutics to Neutral From Overweight

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

Pharmaceutical Technology

2 months ago

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

MT Newswires

2 months ago

FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

PR Newswire

2 months ago

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

MT Newswires

2 months ago

Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy

MT Newswires

2 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,773,790, According to a Recent SEC Filing

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

PR Newswire

2 months ago

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Avid Bioservices Inc Earnings Call

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Zacks

3 months ago

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Zacks

3 months ago

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Halozyme to Present at Upcoming Investor Conferences

PR Newswire

3 months ago

Halozyme to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks in the United States

Argus Research

3 months ago

HALO: Raising target price to $74.00

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

3 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Halozyme Earnings, Guidance Point to Bullish Future

FX Empire

3 months ago

Halozyme Earnings, Guidance Point to Bullish Future

MT Newswires

3 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,228,020, According to a Recent SEC Filing

Argus Research

3 months ago

HALO: Raising target price to $70.00

Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)

GuruFocus.com

3 months ago

Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)

MT Newswires

3 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,689,294, According to a Recent SEC Filing

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Zacks

4 months ago

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Zacks

4 months ago

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

MT Newswires

4 months ago

Morgan Stanley Raises Price Target on Halozyme Therapeutics to $64 From $59, Keeps Overweight Rating

Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare

Zacks

4 months ago

Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Zacks

4 months ago

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

Zacks

4 months ago

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Investor's Business Daily

4 months ago

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Associated Press Finance

4 months ago

Halozyme Therapeutics: Q2 Earnings Snapshot

MT Newswires

4 months ago

Halozyme Therapeutics Q2 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Set

Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts

Investor's Business Daily

4 months ago

Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire

4 months ago

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

Zacks

4 months ago

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Zacks

4 months ago

Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Zacks

4 months ago

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

Zacks

4 months ago

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

5 Biotech Stocks to Bet On Bright Industry Prospects

Zacks

4 months ago

5 Biotech Stocks to Bet On Bright Industry Prospects

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Zacks

4 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Zacks

4 months ago

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

MT Newswires

4 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,100,023, According to a Recent SEC Filing

Argus Research

4 months ago

HALO: What does Argus have to say about HALO?

MT Newswires

4 months ago

Halozyme Therapeutics Insider Sold Shares Worth $269,662, According to a Recent SEC Filing

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Zacks

4 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy

Zacks

4 months ago

Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy

Halozyme to Report Second Quarter 2024 Financial and Operating Results

PR Newswire

4 months ago

Halozyme to Report Second Quarter 2024 Financial and Operating Results

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

Zacks

4 months ago

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

Share on Social Networks: